Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This company MYMX better not wait to long on Covid or they will miss a great op to bring to dollars! Insiders control the outcome here!!
Boy! What a switch from you extrinsic, Do you believe!
Look's like this company does not want to be LEVERAGED! Insiders better wake up!! It's up to Mr. K to kick them were it hurts, and get this going! WE WANT ANSWERS!!
Very nice!! Sunstone/Anergis SA
Its lead program, AllerT, for the treatment of birch pollen allergy has completed phase IIb clinical development.
https://sunstone.eu/portfolio/anergis/
This is going much lower !!!!!!!! You can not hold it up for all! Kempers needs to bring big news! If that ever happens!!
You are absolutely right my friend! Nice to here from you again! Kempers sure can bring this to dollars if he fights for it!! I still have faith in him to bring this to dollars. :) You need to post more often, We all like to hear from you!! :)
And all CEO Before Ronnie were doing a great job! It's the INSIDERS that held back all things to make this company great! If the INSIDERS would let this company succeed, This stock would be in dollars by now!!
CAN RONNIE KEMPERS COME OUT AND PLAY!!
YA! SF has more experience than him! Linkedin said so!!
SYLVAIN FLEURY
Specialties: -Experience as Executive Manager
-Experience in auditing products and companies
-Experience in license agreement with biotech companies
-Management of mutidisciplinary groups in USA and Europe
-Developing scientific and partnership strategies
-Expertise in antigen (peptides & recombinant proteins) and vaccine designs (using VLPs)
-Expertise in mucosal immunology as front line defense against infectious pathogens
-Pre-clinical & clinical trial design and overall management
-Experience in fund rising with venture capitals, bankers, private investors and non-profit organizations in Europe and USA
Courtesy of LINKEDIN
Ronnie must be back playing his VIDEO GAMES again!! LMAO
Virosomes represent an innovative, broadly applicable drug carrier systems that have been applied commonly in various treatments and preventions of cancer, neurodegenerative disorders and infectious diseases. To date, a large number of pharmaceutically active substances like antibiotics, cytostatics, nucleic acids, fungicides and antigens can be encapsulated into the virosomal carrier.
https://www.creative-biolabs.com/lipid-based-delivery/virosomes-based-drug-delivery-service.htm
Efficient delivery of DNA to dendritic cells mediated by influenza virosomes
Maria Grazia Cusi 1, Chiara Terrosi, Gianni Gori Savellini, Giuseppa Di Genova, Rinaldo Zurbriggen, Pierpaolo Correale
Affiliations collapse
Affiliation
1Department of Molecular Biology, Microbiology Section, University of Siena, Via Laterina 8, 53100 Siena, Italy. cusi@unisi.it
Subsequent mRNA analysis of these lymph nodes showed that the trans-gene delivered by the virosomes was effectively expressed as mRNA. Finally, a further cytofluorimetric analysis performed on human DC-enriched-PMBC, infected in vitro with labeled DNA/IRIV lead to the conclusion that the majority of APC (DC, B lymphocytes and CD16+ cells) are able to incorporate the labeled DNA transported by the construct. These findings suggest that the virosome is an efficient delivery system for testing infectious, as well as anti-cancer, DNA-based vaccine research.
https://pubmed.ncbi.nlm.nih.gov/14741166/
Tapping the immunological imprints to design chimeric SARS ...
europepmc.org › article › MED
May 12, 2021 · Influenza virosomes have also been used as an adjuvant and carrier system owing to its excellent antigen delivery mechanism to the target sites . Structurally the modified virus is composed of unilamellar phospoholipid membrane incorporating surface hemagglutinin (HA) and neuraminidase (NA) antigen but lacks the viral inner core and genetic ..
Conclusions
The disease manifestation of COVID-19 has similarities with seasonal flu caused by influenza viruses. The ultimate goal is to design a universal vaccine for influenza, SARS-CoV-2 or other coronaviruses.
Abstract
Nevertheless, the accumulation of mutations in the receptor-binding domain (RBD) might reduce the vaccine efficacy in all age groups. We also propose the concept of chimeric vaccines based on the co-expression of SARS-CoV-2 spike and influenza hemagglutinin (HA) and matrix protein 1 (M1) proteins to generate chimeric virus-like particles (VLP). This review discusses the possible approaches by which influenza-specific memory repertoire developed during the lifetime of the elderly populations can converge to mount an effective immune response against the SARS-CoV-2 spike protein with the possibilities of designing single vaccines for COVID-19 and influenza. Highlights Immunosenescence aggravates COVID-19 symptoms in elderly individuals. Low immunogenicity of SARS-CoV-2 vaccines in elderly population. Tapping the memory T and B cell repertoire in elderly can enhance vaccine efficiency. Chimeric vaccines can mount effective immune response against COVID-19 in elderly. Chimeric vaccines co-express SARS-CoV-2 spike and influenza HA and M1 proteins.
https://europepmc.org/article/MED/33978550#S0007
I see this paper goes way back to 2013 Iran-Virosomes.
Reconstruction of H3N2 influenza virus based virosome in-vitro
Asghar Abdoli,1 Hoorieh Soleimanjahi,1,* Masoumeh Tavassoti Kheiri,2,* Abbas Jamali,2 Hesam Sohani,2 Mohsen Abdoli,2 and Hamid Reza Rahmatollahi2
Author information Article notes Copyright and License information Disclaimer
1Department of Virology, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran
2Influenza Research Lab, Pasteur Institute of Iran, Tehran, Iran
* Corresponding author: Hoorieh Soleimanjahi Ph.D., Address: Virology Department, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran. Tel: +98-21-82883561. Fax: +98-21-82883581. E-mail: ri.ca.seradom@h_mielos
* Corresponding author: Masoumeh Tavassoti Kheiri Ph.D., Address: Influenza Research Lab, Pasteur Institute of Iran, Tehran, Iran. Tel: +98-21-664 96517. Fax: +98-21-664 96517. E-mail: moc.liamg@iriehktm
TOON STEGMANN IN THIS PAPER!!
In 1987, Stegmann et al. described a new procedure for the construction of influenza virosomes by reconstitution of virus-like particles only from viral membrane phospholipids and glycoproteins (2). Afterwards, virosomes have been prepared from numerous enveloped viruses such as influenza virus, Sendai virus, Semliki Forest virus, VSV, Sindbis virus, Epstein-Barr virus, Human Immunodeficiency virus (HIV), Friend Murine Leukaemia virus, HSV and New Castle disease virus (3)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696854/
Comparison of Virosome vs. Liposome as drug delivery vehicle ...
europepmc.org › article › MED
Mar 25, 2021 · Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment. Liu H , Tu Z , Feng F , Shi H , Chen K , Xu X Acta Pharm , 65(2):105-116, 01 Jun 2015
Author: Varun Kumar, Ramesh Kumar, V. K. Jain, Suman Nagpal
Publish Year: 2021
https://europepmc.org/article/MED/33719838
Targeted Drug Delivery
Ideally one would like to be able to target drug delivery to selected tissues. One can tailor virosomes to targets by incorporating specific molecules (e.g., Fab fragments and ligands) into the virosome's composition. The feasibility of targeted delivery of anticancer drugs by means of virosomal carrier has been demonstrated recently by two independent approaches. In one, a MAb cross-linked to the surface of virosomes mediated specific targeting of the virosomal carrier containing an anticancer drug (e.g., doxorubicin) to human cancer cells. MAbs can bind specifically to cancer-related antigens, providing a means to target systemically administered virosomes to cancerous tissues. Alternatively, ligands that bind surface receptors on the target cells also can be bound to the virosomes to achieve targeted drug delivery. Tumors of mice treated with targeted drug-loaded virosomes failed to grow, and mortality of these animals was significantly reduced. These positive results will definitely open a new field of applications for virosomal technology.18,19
https://www.biopharminternational.com/view/virosomes-novel-strategy-drug-delivery-and-targeting
Definition:
virus-like particle (VY-rus-like PAR-tih-kul) listen
A small particle that contains certain proteins from the outer coat of a virus. Virus-like particles do not contain any genetic material from the virus and cannot cause an infection. They are used to make vaccines that can help the body’s immune system kill microorganisms and certain cancer cells. Virus-like particles were used to make vaccines that prevent cervical cancer caused by human papilloma viruses (HPV). They were also used to make vaccines that prevent liver cancer caused by infection with the hepatitis B virus.
How do HPV vaccines work?
The current HPV vaccines are based on virus-like particles (VLPs) that are formed by HPV surface components. VLPs are not infectious because they lack the virus’s DNA. However, they closely resemble the natural virus, and antibodies against the VLPs also have activity against the natural virus. The VLPs have been found to be strongly immunogenic, which means that they induce high levels of antibody production by the body. This makes the vaccines highly effective.
The vaccines do not prevent other sexually transmitted diseases, nor do they treat existing HPV infections or HPV-caused disease.
Gardasil-MERCK using VIROSOMES AS A DELIVERY SYSTEM
https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-vaccine-fact-sheet
Nice POST FRIENDS!! :) SP1 & Phosphene
https://www.reddit.com/r/Mymetics_Stock/comments/nkg2ct/lots_of_dd_on_ihub/
(PDF) Gastro-intestinal delivery of influenza subunit vaccine ...
www.academia.edu › 19350165 › Gastro_intestinal
Gram-positive enhancer matrix (GEM) particles are a novel adjuvant produced from the food-grade, non-pathogenic and non-colonizing gram-positive bacterium Lactococcus lactis [34, 35]. L. lactis is approved by the regulatory agencies for human use and considered as a generally recognized as safe (GRAS) organism.
ISBN: 978-90-367-4601-4 (Printed Version)978-90-367-4600-7 (Electronic Version)Layout
&
printing: O? Page, Amsterdam Printing of this thesis was supported by generous con-tribution from the University of Groningen, Groningen Graduate School of Science and Mucosis BV
.Copyright © 2010 by Vinay Saluja. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior written permission of the author.
UNIVERSITY OF GRONINGEN
NOVEL PERSPECTIVES FOR INFLUENZA VACCINE FORMULATION AND ADMINISTRATION
L. lactis
cell wall derived adjuvant, stable dry powder vaccines and mucosal vaccine delivery
Dissertation holder for a PhD in Mathematics and Natural Sciences at the University of Groningen on the authority of the Rector Magnificus, Dr. F. Zwarts, to be defended in public on Friday, December 3, 2010 at 11 a.m.
Vinay Saluja
born on February 23, 1982 in Jaipur, India
https://www.academia.edu/19350165/Gastro_intestinal_delivery_of_influenza_subunit_vaccine_formulation_adjuvanted_with_Gram_positive_enhancer_matrix_GEM_particles
The Immunotherapy laboratory of the Department of Medical Oncology of the VU University Medical Center studies the possibility to exploit the immune system to specifically recognize, attack and eradicate tumor cells. Key components in a successful immune reaction are two types of immune effector cells: the Dendritic Cells (DCs) and the T cells. DCs are the sentinels of our immune system which, in case of danger (e.g. viral or bacterial infections, inflammation or tumor growth), become activated and release factors that recruit other immune cells to contribute to an effective anti-tumor immune response. A central role in the immune-mediated elimination of tumors is played by Cytotoxic (or ?killer?) T Lymphocytes (CTLs). In lymph nodes that drain tumor sites these CTLs are instructed by DCs (migrated from the tumor) to recognize and kill tumor cells. A major obstacle in this process is caused by immune suppressive factors produced by the tumor that hamper the development and proper activation of both DCs and CTLs. As a result, patients are more susceptible to microbial infections and unable to mount an effective immune response to their tumor. Much of our research is aimed at overcoming this immune suppression.
https://www.vumc.com/departments/medical-oncology/research/immunotherapy-laboratory.htm
Ronald! Ronald! Ronald! were is are big PR!!!!!!!!!!!!!!!!!!!!!
Get off the pot MYMX!! https://www.toonpool.com/user/856/files/toilet_533025.jpg
Although virosomes are well known to bind with several synthetic drugs (doxorubicin, methotrexate etc.) by earlier authors for their controlled and targeted delivery
Preparation and characterization of nanocurcumin based hybrid ...
www.nature.com › articles › s41598/020/79631-1
Jan 11, 2021 · Although virosomes are well known to bind with several synthetic drugs (doxorubicin, methotrexate etc.) by earlier authors for their controlled and targeted delivery 12, 13, but there is no report...
https://www.nature.com/articles/s41598-020-79631-1
Targeting HER-2/neu with Antirat Neu Virosomes for Cancer Therapy
cancerres.aacrjournals.org › content › canres
use of doxorubicin (Doxo) as a cytotoxic drug. We have used virosomes (Vir; reconstituted fusion-active viral envelopes) as a new drug delivery system and have shown that Vir are capable of binding and penetrating into tumor cells, delivering cytotoxic drugs. We have additionally demon-strated that conjugating Fab fragments of an antirat Neu ...
[CANCER RESEARCH 62, 437–444, January 15, 2002]
Targeting HER-2/neu with Antirat Neu Virosomes for Cancer Therapy1
Ernst Waelti,2 Nina Wegmann,2 Ruth Schwaninger, Antionette Wetterwald, Carsten Wingenfeld,
Barbara Rothen-Rutishauser, and Claude D. Gimmi3
Department of Clinical Research [W. N., S. R., W. A., W. C., C. D. G.], Institute of Pathology [W. E.], and Institute of Anatomy [R-R. B.], University of Bern, 3010 Bern,
https://cancerres.aacrjournals.org/content/canres/62/2/437.full.pdf
Nanotechnology Based Virosomal Drug Delivery Systems
www.ommegaonline.org › article-details
Dec 15, 2014 · Fab'-Doxo- virosomes combined the anti-proliferate properties of the monoclonal antibody and the cytotoxic effect of doxorubicin in vivo. Fab'-Doxo-virosomes significantly inhibited tumour formation at a tumour load of metastasis spread, indicating that this can also be considered to be a promising new selective drug delivery system for the treatment of tumours expressing a specific tumour antigen.
Author: Basavaraj K. Nanjwade, Nagi F. Idris, Ramchandra N. Chilkawar, Teerapol Srichana, Azam Sharif Md. Sh...
Cited by: 1
US Patent for Methods for providing adjuvanted virosomes and ...
patents.justia.com › patent › 10588963
Sep 12, 2014 · Bungener, Laura, et al. “A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease.” Antiviral therapy 11.6 (2006): 717. Bungener, Laura, et al. “Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.”
https://patents.justia.com/patent/10588963
Nanoparticle Vaccines Adopting Virus-like Features for ...
www.ntno.org › v01p0244
Jun 09, 2017 · 44. Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T. et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine. 2002;20:2287-95 45. Angel J, Chaperot L, Molens J-P, Mezin P, Amacker M, Zurbriggen R. et al. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine. 2007;25:3913-21
https://www.ntno.org/v01p0244.htm
Tetramers (multimeric peptide-MHC complexes)
I STAND CORRECTED THAT THIS IS 100% INSTEAD OF 70%
a study on the use of an alphavirus vector expressing HPV proteins we demonstrated that immunization with recombinant virus expressing a fusion protein of E6 and E7 resulted in a strongly enhanced immune and anti-tumor response (i.e. 100% protection), as compared to the single proteins or their combination. These studies, demonstrating (i) the effectiveness of virosomes as an antigen-carrier system for protein antigens and (ii) the potency of the E6,7 fusion protein provide a solid base for the development of an effective virosome-based immunization strategy against cervical carcinoma.
https://www.narcis.nl/research/RecordID/OND1242943
THIS SHOULD BE A VACCINE IN THE MARKET ALREADY! COME ON RK!!
In tumour challenge experiments, immunization of mice with E7-containing virosomes prevented tumour outgrowth in >70% of the animals. Thus, influenza-derived virosomes with encapsulated HPV E7 protein antigen act as an excellent vaccine delivery system for induction of cellular immunity against HPV-transformed cells and represent a promising immunotherapeutic vaccine for the treatment of (precursor lesions of) cervical cancer.
http://europepmc.org/article/MED/17310816
In tumour challenge experiments, immunization of mice with E7-containing virosomes prevented tumour outgrowth in >70% of the animals. Thus, influenza-derived virosomes with encapsulated HPV E7 protein antigen act as an excellent vaccine delivery system for induction of cellular immunity against HPV-transformed cells and represent a promising immunotherapeutic vaccine for the treatment of (precursor lesions of) cervical cancer.
http://europepmc.org/article/MED/17310816
A review of the RSV vaccine landscape - WHO
www.who.int › immunization › research
MERCK SH protein Ghent University M ARKET APPROVED PRECLI N I CAL PH ASE I PH ASE I I PH ASE I I I Medi-RSV 4M2-2 LID/NIAID/NIH Medi-559, RSV LID/NIAID/NIH RSV 4 NS2 41313 LID/NIAID/NIH Peptide microparticle Particle-Based VLP Virosome Virosome BLP VLP VLP Univer sity of Pittsbur gh Mucosis Nucleic Acid Whole-Inactivated Gene-Based Vectors ...
https://www.who.int/immunization/research/meetings_workshops/Review_RSV_vaccine_landscape_Karron.pdf?ua=1
European Investment Bank’s €20 Million Financing Agreement With BioVersys
April 16, 2021 Federica Tiefenthaler
Law Firms: Pestalozzi;
Clients: European Investment Bank
https://www.globallegalchronicle.com/european-investment-banks-e20-million-financing-agreement-with-bioversys/
Cue Biopharma Collaborates With Merck on Phase I Trial of CUE ...
www.precisiononcologynews.com › cancer › cue
Apr 20, 2020 · The treatment is designed to induce and expand tumor-specific T cells, specifically, HPV16 E7-specific cytotoxic T cells. Having entered into the agreement with Merck, Cue Biopharma will conduct a Phase I study, KEYNOTE-A78, to evaluate the combination of CUE-101 and pembrolizumab.
https://www.precisiononcologynews.com/cancer/cue-biopharma-collaborates-merck-phase-i-trial-cue-101-keytruda-head-and-neck-cancer#.YLZWe4WSnIU
Wouter Koudstaal
Here's one of his preview of papers!
Accomplishments
Wouter has 29 publications29
Publications
LOOKS LIKE HE KNOWS VIROSOMES!! :)
A small-molecule fusion inhibitor of influenza virus is orally active in mice Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening Enhancement of therapeutic potential of a naturally occurring human antibody targeting a phosphorylated Ser422 containing epitope on pathological tau A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities In vitro neutralization is not predictive of prophylactic efficacy of broadly neutralizing monoclonal antibodies CR6261 and CR9114 against lethal H2 influenza virus challenge in mice Immunological memory to hyperphosphorylated tau in asymptomatic individuals HA Antibody-Mediated Fc?RIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies Transient humoral protection against H5N1 challenge after seasonal influenza vaccination of humans A common solution to group 2 influenza virus neutralization Mechanisms of hemagglutinin targeted influenza virus neutralization Highly conserved protective epitopes on influenza B viruses A highly conserved neutralizing epitope on group 2 influenza A viruses Human monoclonal antibodies for prophylaxis and treatment of influenza Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs
Linkedin
Cont" from last post
183VLP Virus like particle Virus Like Particle with RCBSARS-CoV2 Berna Biotech Pharma
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163182950
Virosome - an overview | ScienceDirect Topics
www.sciencedirect.com › topics › immunology-and
The validation of the IRIV concept as a delivery vehicle has been shown through the licensing of IRIV-based vaccines against hepatitis A (Epaxal ®, Berna Biotech, Bern, Switzerland) and influenza (Inflexal ® V, Berna Biotech, Bern, Switzerland; Invivac is a product of Solvay, Weesp, The Netherlands). The IRIV hepatitis A vaccine was the first ...
https://www.sciencedirect.com/topics/immunology-and-microbiology/virosome
THEY STILL KNOW SOMETHING VIROSOMES!
Landscape of candidate vaccines in pre-clinical development Friday, May 28, 2021
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
82PSProtein subunitS1 or RBD proteinSARS-CoV2SARSBaylor College of Medicine
131 VVr Viral vector (Replicating) Replication-competent VSV chimeric virus technology (VSV?G) delivering the SARS-CoV-2 Spike (S) glycoprotein. SARS-CoV2 Ebola, Marburg, Lassa IAVI/Merck
World Health Organization
cdn.who.int › media › docs
Feb 12, 2021 · Replication-competent VSV chimeric virus technology (VSV?G) delivering the SARS-CoV-2 Spike (S) glycoprotein. Ebola, Marburg, Lassa IAVI/Merck Replicating VSV vector-based DC-targeting University of Manitoba VSV-S HIV, MERS University of Western Ontario Aurobindo VSV vector M2-deficient single replication (M2SR) influenza vector
LOOK AT SOME OF THE SIMILARITY'S
Objectives
To enhance the efficiency of influenza virosome-mediated gene delivery by engineering this virosome.
Results
A novel chimeric influenza virosome was constructed containing the glycoprotein of Vesicular stomatitis virus (VSV-G), along with its own hemagglutinin protein. To optimize the transfection efficiency of both chimeric and influenza cationic virosomes, HEK cells were transfected with plasmid DNA and virosomes and the transfection efficiency was assessed by FACS analysis. The chimeric virosome was significantly more efficient in mediating transfection for all amounts of DNA and virosomes compared to the influenza virosome.
Conclusions
Chimeric influenza virosome, including VSV-G, is superior to the conventional influenza virosome for gene delivery.
https://link.springer.com/article/10.1007/s10529-016-2108-1
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159055973
mRNA in an intranasal delivery systemSARS-CoV2eTheRNA
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
Posted May 31st 2021
POSITIVE OUTCOME OF EUROPEAN DECENTRALISED REGISTRATION PROCEDURE FOR STALLERGENES GREER’S SUBLINGUAL HOUSE DUST MITE ALLERGEN IMMUNOTHERAPY TABLET
Stallergenes Greer announces the positive outcome of the European decentralised registration procedure for its sublingual house dust mite (HDM) allergen immunotherapy tablet Actair®.
The Paul-Ehrlich-Institut (PEI), Germany, acted as reference member state on behalf of 21 European countries. Each member state involved in the procedure will now issue individual national marketing authorisations at the end of their national phase.
“We are pleased to have achieved this significant milestone which demonstrates our commitment to patients and marks a major step forward for the company’s further development in the European market. Stallergenes Greer’s sublingual allergen immunotherapy tablet is an important option for people suffering from house dust mite-induced allergic rhinitis or rhinoconjunctivitis and illustrates our engagement to provide patients with a range of administration modes tailored to individual needs and profiles,” declares Michele Antonelli, Chief Executive Officer.
https://www.stallergenesgreer.com/positive-outcome-european-decentralised-registration-procedure-stallergenes-greers-sublingual-house#